(Q38657510)

5 September 2017

1 reference

title

The cellular immunotherapy of cancer: current and potential uses of interleukin-2. (English)

1 reference

5 September 2017

0 references

1 reference

Sondel PM

1

1 reference

5 September 2017

Hank JA

2

1 reference

5 September 2017

Kohler PC

3

1 reference

5 September 2017

Sosman JA

4

1 reference

5 September 2017

Weil-Hillman G

5

1 reference

5 September 2017

Fisch P

6

1 reference

5 September 2017

1 January 1989

1 reference

Critical Reviews in Oncology Hematology

5 September 2017

1 reference

5 September 2017

9

1 reference

5 September 2017

2

1 reference

5 September 2017

125-147

1 reference

TREATMENT OF PRIMARY FIBROSARCOMA IN THE RAT WITH IMMUNE LYMPHOCYTES

5 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2889%2980008-3

7 January 2021

In vitro induction of cell-mediated immunity to murine leukemia cells. II. Cytotoxic activity in vitro and tumor-neutralizing capacity in vivo of anti-leukemia cytotoxic lymphocytes generated in macrocultures

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2889%2980008-3

7 January 2021

Inhibition of established transplants of chemically induced sarcomas in syngeneic mice by lymphocytes from immunized donors

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2889%2980008-3

7 January 2021

Elimination of syngeneic sarcomas in rats by a subset of T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2889%2980008-3

7 January 2021

Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin 2.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2889%2980008-3

7 January 2021

The Choice of Animal Tumors for Experimental Studies of Cancer Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2889%2980008-3

7 January 2021

Cell-Mediated Immunity to Tumor Cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2889%2980008-3

7 January 2021

Immunodiagnosis of acute leukemia: detection of residual disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2889%2980008-3

7 January 2021

Clonal analysis of the cytolytic T-cell response to human tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2889%2980008-3

7 January 2021

Cultured human T-cell lines kill autologous solid tumours

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2889%2980008-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS1040-8428%2889%2980008-3

1 reference

7 January 2021

T lymphocytes: ontogeny, function, and relevance to clinical disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2889%2980008-3

7 January 2021

Genes of the T-cell antigen receptor in normal and malignant T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2889%2980008-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS1040-8428%2889%2980008-3

1 reference

7 January 2021

Molecular aspects of human T lymphocyte antigen recognition

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2889%2980008-3

7 January 2021

Complete primary structure of a heterodimeric T-cell receptor deduced from cDNA sequences.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2889%2980008-3

7 January 2021

Associations Between Major Histocompatibility Antigens and Susceptibility to Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2889%2980008-3

7 January 2021

Homozygous deletions that simultaneously eliminate expressions of class I and class II antigens of EBV-transformed B-lymphoblastoid cells. I. Reduced proliferative responses of autologous and allogeneic T cells to mutant cells that have decreased ex

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2889%2980008-3

7 January 2021

The proliferative immune response to autologous Epstein-Barr virus-transformed lymphoblastoid cells. I. Studies with HLA haplotype loss variants demonstrate a role for MHC-linked genes

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2889%2980008-3

7 January 2021

H-2D (Rfv-1) gene influence on recovery from Friend virus leukemia is mediated by nonleukemic cells of the spleen and bone marrow

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2889%2980008-3

7 January 2021

Allele-specific alien-driven diversity, immune responsiveness and MHC-restriction

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2889%2980008-3

7 January 2021

Remission of relapsed leukaemia during a graft-versus-host reaction. A "graft-versus-leukaemia reaction" in man?

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2889%2980008-3

7 January 2021

Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2889%2980008-3

7 January 2021

Manipulation of graft-versus-host disease for a graft-versus-leukemia effect after allogeneic bone marrow transplantation in AKR mice with spontaneous leukemia/lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2889%2980008-3

7 January 2021

Reactivity of in-vitro-expanded alloimmune cytotoxic T lymphocytes and Qa-1-specific cytotoxic T lymphocytes against AKR leukemia in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2889%2980008-3

7 January 2021

Differential function of major histocompatibility complex antigens in T-lymphocyte activation

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2889%2980008-3

7 January 2021

HLA identical leukemia cells and T cell growth factor activate cytotoxic T cell recognition of minor locus histocompatibility antigens in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2889%2980008-3

7 January 2021

ICAM-1 a ligand for LFA-1-dependent adhesion of B, T and myeloid cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2889%2980008-3

7 January 2021

Functional interaction between human T-cell protein CD4 and the major histocompatibility complex HLA-DR antigen

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2889%2980008-3

7 January 2021

Molecular mechanisms of cytolysis by complement and by cytolytic lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2889%2980008-3

7 January 2021

Identification, isolation, and characterization of a novel cytotoxin in murine cytolytic lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2889%2980008-3

7 January 2021

Resistance of cytotoxic T lymphocytes to the lytic effects of their toxic granules

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2889%2980008-3

7 January 2021

The in vivo distribution of indium-111 labeled in vitro alloactivated syngeneic lymphocytes in a patient with relapsed acute myelomonocytic leukemia: implications for adoptive chemoimmunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2889%2980008-3

7 January 2021

Clinical response of a patient with diffuse histiocytic lymphoma to adoptive chemoimmunotherapy using cyclophosphamide and alloactivated haploidentical lymphocytes. A case report and phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2889%2980008-3

7 January 2021

Clinical adoptive chemoimmunotherapy with allogeneic alloactivated HLA-haploidentical lymphocytes: controlled induction of graft-versus-host-reactions

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2889%2980008-3

7 January 2021

Adoptive immunotherapy of metastatic B16 melanoma with allogeneic immune cells sensitized to minor histocompatibility antigens

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2889%2980008-3

7 January 2021

Natural killer cells: their roles in defenses against disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2889%2980008-3

7 January 2021

Selective in Vitro Growth of T Lymphocytes from Normal Human Bone Marrows

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2889%2980008-3

7 January 2021

Interleukin 2: Biology and biochemistry

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2889%2980008-3

7 January 2021

The functional relationship of the interleukins

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2889%2980008-3

7 January 2021

Interleukin 2 high-affinity receptor expression requires two distinct binding proteins

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2889%2980008-3

7 January 2021

Novel interleukin 2 (IL-2) receptor appears to mediate IL-2-induced activation of natural killer cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2889%2980008-3

7 January 2021

Interleukin 2 and its receptor: structure, function and therapeutic potential

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2889%2980008-3

7 January 2021

Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2889%2980008-3

7 January 2021

The differential inhibitory effects exerted by cyclosporine and hydrocortisone on the activation of human cytotoxic lymphocytes by recombinant interleukin-2 versus allospecific CTL

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2889%2980008-3

7 January 2021

The human lymphokine-activated killer cell system. V. Purified recombinant interleukin 2 activates cytotoxic lymphocytes which lyse both natural killer-resistant autologous and allogeneic tumors and trinitrophenyl-modified autologous peripheral bloo

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2889%2980008-3

7 January 2021

Inhibition of clonogenic growth of fresh leukemia cells by unstimulated and IL-2 stimulated NK cells of normal donors

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2889%2980008-3

7 January 2021

Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2889%2980008-3

7 January 2021

Recombinant interleukin-2 directly augments the cytotoxicity of human monocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2889%2980008-3

7 January 2021

Generation of monoclonal antibodies to a human natural killer clone. Characterization of two natural killer-associated antigens, NKH1A and NKH2, expressed on subsets of large granular lymphocytes.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2889%2980008-3

7 January 2021

Lymphokine-activated killer (LAK) cells. Analysis of factors relevant to the immunotherapy of human cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2889%2980008-3

7 January 2021

Nonrestricted cytotoxicity mediated by interleukin 2-expanded leukocytes is inhibited by anti-LFA-1 monoclonal antibodies (MoAb) but potentiated by anti-CD3 MoAb

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2889%2980008-3

7 January 2021

Endothelial cell lysis induced by lymphokine-activated human peripheral blood mononuclear cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2889%2980008-3

7 January 2021

'Nonspecific' MHC-unrestricted killer cells and their receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2889%2980008-3

7 January 2021

New perspectives in cell adhesion: RGD and integrins

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2889%2980008-3

7 January 2021

Human natural killer cells and cytotoxic T lymphocytes require cell surface carbohydrate determinants for lytic function

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2889%2980008-3

7 January 2021

A novel 120-kD surface antigen expressed by a subset of human lymphocytes. Evidence that lymphokine-activated killer cells express this molecule and use it in their effector function

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2889%2980008-3

7 January 2021

Selective lysis of target cells by interleukin-2-expanded peripheral blood mononuclear leukocyte clones

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2889%2980008-3

7 January 2021

The molecular basis for cytolytic T lymphocyte function: analysis with blocking monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2889%2980008-3

7 January 2021

Reduced incidence of hepatic metastases by perioperative treatment with recombinant human interleukin-2.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2889%2980008-3

7 January 2021

Structure and expression of a cloned cDNA for human interleukin-2.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2889%2980008-3

7 January 2021

Biological Activity of Recombinant Human Interleukin-2 Produced inEscherichia coli

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2889%2980008-3

7 January 2021

Phase I evaluation of recombinant interleukin-2 in patients with advanced malignant disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2889%2980008-3

7 January 2021

Phase I study of the adoptive immunotherapy of human cancer with lectin activated autologous mononuclear cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2889%2980008-3

7 January 2021

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2889%2980008-3

7 January 2021

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2889%2980008-3

7 January 2021

Immunotherapy of cancer using interleukin 2: current status and future prospects

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2889%2980008-3

7 January 2021

The emergence of biologicals as cancer treatment: the good news and the bad

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2889%2980008-3

7 January 2021

Repetitive weekly cycles of recombinant human interleukin-2: responses of renal carcinoma with acceptable toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2889%2980008-3

7 January 2021

Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2889%2980008-3

7 January 2021

Adoptive immunotherapy for stage IV renal cell carcinoma: a novel protocol utilizing periodate and interleukin-2-activated autologous leukocytes and continuous infusions of low-dose interleukin-2.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2889%2980008-3

7 January 2021

Influence of dose and duration of infusion of interleukin-2 on toxicity and immunomodulation

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2889%2980008-3

7 January 2021

In vivo and in vitro activation of natural killer cells in advanced cancer patients undergoing combined recombinant interleukin-2 and LAK cell therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2889%2980008-3

7 January 2021

Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2889%2980008-3

7 January 2021

Treatment of adenocarcinoma in the peritoneum of mice: chemoimmunotherapy with IL-2-stimulated cytotoxic lymphocytes as a model for treatment of minimal residual disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2889%2980008-3

7 January 2021

Specific targeting of human peripheral blood T cells by heteroaggregates containing anti-T3 crosslinked to anti-target cell antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2889%2980008-3

7 January 2021

Hormone conjugated with antibody to CD3 mediates cytotoxic T cell lysis of human melanoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2889%2980008-3

7 January 2021

Interaction of recombinant interferons with recombinant interleukin-2: differential effects on natural killer cell activity and interleukin-2-activated killer cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2889%2980008-3

7 January 2021

10.1016/S1040-8428(89)80008-3

Identifiers

DOI

1 reference

5 September 2017

1 reference